AURYXIA Film-coated tablet Ref.[10060] Active ingredients: Ferric citrate

Source: FDA, National Drug Code (US)  Revision Year: 2019 

1. Indications and Usage

Hyperphosphatemia in Chronic Kidney Disease on Dialysis

Auryxia is indicated for the control of serum phosphorus levels in adult patients with chronic kidney disease on dialysis.

Iron Deficiency Anemia in Chronic Kidney Disease Not on Dialysis

Auryxia is indicated for the treatment of iron deficiency anemia in adult patients with chronic kidney disease not on dialysis.

2. Dosage and Administration

2.1 Dosage for Hyperphosphatemia in Chronic Kidney Disease on Dialysis

The recommended starting dose is 2 tablets orally 3 times per day with meals. Monitor serum phosphorus levels and titrate the Auryxia dose in decrements or increments of 1 to 2 tablets per day as needed to maintain serum phosphorus at target levels, up to a maximum dose of 12 tablets daily. Dose can be titrated at 1-week or longer intervals.

In a clinical trial, patients required an average of 8 to 9 tablets a day to control serum phosphorus levels.

2.2 Dosage for Iron Deficiency Anemia in Chronic Kidney Disease Not on Dialysis

The recommended starting dose is 1 tablet orally 3 times per day with meals. Titrate the dose of Auryxia as needed to achieve and maintain hemoglobin at target levels, up to a maximum dose of 12 tablets daily.

In a clinical trial in patients with chronic kidney disease not on dialysis (CKD-NDD), patients required an average of 5 tablets per day to increase hemoglobin levels.

10. Overdosage

No data are available regarding overdose of Auryxia in patients. In patients with chronic kidney disease, the maximum dose studied was 2,520 mg ferric iron (12 tablets of Auryxia) per day. Iron absorption from Auryxia may lead to excessive elevations in iron stores, especially when concomitant intravenous iron is used [see Warnings and Precautions (5.1)].

In clinical trials, one case of elevated iron in the liver as confirmed by biopsy was reported in a patient on dialysis administered intravenous iron and Auryxia.

16.2. Storage and Handling

Store at 20 to 25°C (68 to 77°F): excursions permitted to 15° to 30°C (59°F to 86°F) [See USP controlled room temperature]. Protect from moisture.

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.